KEGG   DRUG: D03058Help
Entry
D03058                      Drug                                   

Name
Basiliximab (genetical recombination) (JAN);
Basiliximab (USAN/INN);
Simulect (TN)
Product
Activity
Immunosuppressant [monoclonal antibody] [DS:H00083]
Remark
Therapeutic category: 
ATC code: 
Comment
anti-CD25 monoclonal antibody
Target
CD25 [HSA:3559] [KO:K05068]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04144  Endocytosis
hsa04630  Jak-STAT signaling pathway
hsa04640  Hematopoietic cell lineage  
 
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC02 Basiliximab
      D03058  Basiliximab (genetical recombination) (JAN); Basiliximab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D03058  Basiliximab (genetical recombination) (JAN); Basiliximab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokine receptors
  Class I cytokine receptors (hematopoietin family receptors)
   interleukin 2 receptor alpha (CD25)
    Basiliximab
     D03058  Basiliximab (genetical recombination) (JAN); Basiliximab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
179045-86-4
PubChem: 
DrugBank: 
NIKKAJI: 

» Japanese version   » Back

DBGET integrated database retrieval system